- Home
- Companies
- Vivozon Inc.
- Products
Vivozon Inc. products
Vivozon - Opiranserin
Opiranserin (VVZ-149) for injection is a first-in-class non-narcotic analgesic under development by Vivozon. As atreatment for postoperative pain used as a first-line therapy in the global market, Opiranserin aims to ultimately replaceopioid analgesics by providing an effective and safe solution for pain management. With the hope to combat opioidmisuse and abuse, Opiranserin is currently undergoing phase 3 clinical trials in Korea and the United States.
Vivozon - Treating Chronic Pain Including Neuropathic Pain
On July 29, 2020, Vivozon applied for a patent for a second pipeline, VVZ-2471, and is currently conducting non-clinical toxicity studies. VVZ-2471 is a new drug candidate for treating chronic pain including neuropathic pain. Recently, the prevention and treatment potential of drug (morphine) addiction, anxiety, and depression have also been demonstrated through non-clinical studies. Upon completion of non-clinical trials for VVZ-2471, Vivozon plans to embark on clinical trials as soon as possible.
Clinical Development of Opiranserin for Injection
Vivozon - Analgesic Efficacy and Safety of VVZ-149 Injection
A randomized, double-blind, parallel-group, placebo-controlled clinical trial to evaluate the analgesic efficacy and safety of VVZ-149 Injection in patients who have pain after laparoscopic and robotic-laparoscopic gastrectomy.
Vivozon - Pharmacokinetics of VVZ-149 Injection
Single-dose, escalation clinical trial to evaluate the safety and pharmacokinetics of VVZ-149 injection in healthy elderly men
Vivozon - Pharmacokinetics of VVZ-149 Injection
A randomized, double-blind, placebo-controlled, single and repeated dose, escalation clinical trial to evaluate the safety, tolerability, and pharmacokinetics of VVZ-149 injection in healthy adult males